# Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

> **NCT01033825** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 310 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** Ciclesonide HFA Nasal Aerosol 320 mcg
- **DRUG:** Ciclesonide HFA Nasal Aerosol 160 mcg
- **DRUG:** HFA Nasal Aerosol placebo
- **DRUG:** Ciclesonide Aqueous Nasal Spray 200 mcg
- **DRUG:** AQ Nasal Spray Placebo
- **DRUG:** Placebo plus Dexamethasone HFA
- **DRUG:** Placebo AQ plus Dexamethasone 6 mg

## Key facts

- **NCT ID:** NCT01033825
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033825, "Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01033825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*